IDEXX Laboratories, Inc.· IDXX

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

• 

  Insights Into Idexx (IDXX) Q2: Wall Street Projections for Key Metrics

  Evaluate the expected performance of Idexx (IDXX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

  Jul 31, 2026
• 

  IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals

  WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX releases 2025 Corporate Responsibility Report highlighting progress against its goals and commitments.

  Jul 28, 2026
• 

  American Capital Management Inc. Has $93.31 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

  American Capital Management Inc. reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 8.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 166,056 shares of the company's stock after selling 15,689 shares during the

  Jul 28, 2026
• 

  IDEXX Laboratories, Inc. $IDXX Shares Sold by Bank of Nova Scotia

  Bank of Nova Scotia lessened its stake in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 11.1% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 11,124 shares of the company's stock after selling 1,383 shares during the quarter. Bank of Nova Scotia's holdings in IDEXX Laboratories were

  Jul 28, 2026
• 

  Allspring Global Investments Holdings LLC Sells 3,332 Shares of IDEXX Laboratories, Inc. $IDXX

  Allspring Global Investments Holdings LLC cut its stake in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 7.2% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 43,198 shares of the company's stock after selling 3,332 shares during the quarter. Allspring Global Investments Holdings

  Jul 21, 2026

• UB

  Idexx Laboratories price target lowered to $640 from $730 at UBS

  UBS· Andrea Alfonso· $640.00
  Apr 28, 2026
• BA

  Idexx Laboratories price target lowered to $800 from $850 at Barclays

  Barclays· Glen Santangelo· $800.00
  Feb 5, 2026
• UB

  Idexx Laboratories price target lowered to $730 from $750 at UBS

  UBS· Andrea Alfonso· $730.00
  Feb 3, 2026
• BA

  Idexx Laboratories initiated with an Overweight at Barclays

  Barclays· Glen Santangelo· $850.00
  Dec 8, 2025
• JE

  IDEXX Laboratories (IDXX) PT Raised to $830 at Jefferies

  Jefferies· Keith Devas· $830.00
  Nov 4, 2025